Portal de Periódicos da CAPES

Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein

2003; Springer Nature; Volume: 22; Issue: 16 Linguagem: Inglês

10.1093/emboj/cdg410

1460-2075

X. Na,

Cancer, Hypoxia, and Metabolism

Article15 August 2003free access Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel—Lindau protein Xi Na Xi Na Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Hai Ou Duan Hai Ou Duan Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Edward M. Messing Edward M. Messing Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA The James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Susan R. Schoen Susan R. Schoen Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Charlotte K. Ryan Charlotte K. Ryan Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author P.Anthony di Sant'Agnese P.Anthony di Sant'Agnese Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Erica A. Golemis Erica A. Golemis Division of Basic Sciences, Fox Chase Cancer Center, Philadelphia, PA, 19111 USA Search for more papers by this author Guan Wu Corresponding Author Guan Wu Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA The James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Xi Na Xi Na Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Hai Ou Duan Hai Ou Duan Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Edward M. Messing Edward M. Messing Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA The James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Susan R. Schoen Susan R. Schoen Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Charlotte K. Ryan Charlotte K. Ryan Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author P.Anthony di Sant'Agnese P.Anthony di Sant'Agnese Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA Search for more papers by this author Erica A. Golemis Erica A. Golemis Division of Basic Sciences, Fox Chase Cancer Center, Philadelphia, PA, 19111 USA Search for more papers by this author Guan Wu Corresponding Author Guan Wu Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA The James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA Search for more papers by this author Author Information Xi Na1,2, Hai Ou Duan2, Edward M. Messing1,2,3, Susan R. Schoen1, Charlotte K. Ryan2, P.Anthony di Sant'Agnese2, Erica A. Golemis4 and Guan Wu 1,2,3 1Department of Urology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA 2Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642 USA 3The James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 656, Rochester, NY, 14642 USA 4Division of Basic Sciences, Fox Chase Cancer Center, Philadelphia, PA, 19111 USA *Corresponding author. E-mail: [email protected] The EMBO Journal (2003)22:4249-4259https://doi.org/10.1093/emboj/cdg410 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Inactivation of the von Hippel—Lindau (VHL) tumor suppressor gene is linked to the hereditary VHL disease and sporadic clear cell renal cell carcinomas (CCRCC). VHL-associated tumors are highly vascularized, a characteristic associated with overproduction of vascular endothelial growth factor (VEGF). The VHL protein (pVHL) is a component of the ubiquitin ligase E3 complex, targeting substrate proteins for ubiquitylation and subsequent proteasomic degradation. Here, we report that the pVHL can directly bind to the human RNA polymerase II seventh subunit (hsRPB7) through its β-domain, and naturally occurring β-domain mutations can decrease the binding of pVHL to hsRPB7. Introducing wild-type pVHL into human kidney tumor cell lines carrying endogenous mutant non-functional pVHL facilitates ubiquityl ation and proteasomal degradation of hsRPB7, and decreases its nuclear accumulation. pVHL can also suppress hsRPB7-induced VEGF promoter transactivation, mRNA expression and VEGF protein secretion. Together, our results suggest that hsRPB7 is a downstream target of the VHL ubiquitylating complex and pVHL may regulate angiogenesis by targeting hsRPB7 for degradation via the ubiquitylation pathway and preventing VEGF expression. Introduction von Hippel—Lindau (VHL) disease is a rare hereditary multiorgan neoplastic disorder, transmitted by the mutant VHL gene (Maher and Kaelin, 1997; Stolle et al., 1998). VHL patients develop tumors in several discrete organ systems, including hemangioblastomas in the central nervous system and retina, clear cell carcinomas of the kidney, pheochromocytomas of the adrenal gland, cysts/adenomas and islet cell tumors of the pancreas, cystadenomas of the epididymis and endolymphatic sac tumors of the inner ear (Maher and Kaelin, 1997; Stolle et al., 1998). More importantly, the VHL gene is inactivated in ∼50–80% of the common sporadic form of clear cell renal cell carcinoma (CCRCC) (Foster et al., 1994; Gnarra et al., 1994; Shuin et al., 1994). The VHL protein (pVHL) has been demonstrated to associate with a multiprotein complex with components including elongin C (EC), elongin B (EB), cullin-2 (CUL-2) and Rbx1 to form a complex called VCB—CUL-2 (Pause et al., 1997; Kamura et al., 1999; Skowyra et al., 1999). In light of the structural analogy of VCB—CUL-2 to SCF (Skp1—Cdc53 or Cullin—F-box) ubiquitin ligase, several groups have demonstrated that the VCB—CUL-2 complex functions as a ubiquitin ligase (Iwai et al., 1999; Lisztwan et al., 1999). The ubiquitin—proteasome degradation system has been shown to control the abundance and activity of several oncogene and tumor suppressor gene products, transcription factors and other signaling molecules (Baumeister et al., 1998; Hershko and Ciechanover, 1998). The crucial substrate-recognition step in ubiquitin-dependent proteolysis is mediated by the diverse family of E3 ubiquitin ligases. pVHL contains two domains, an α-domain and a β-domain (Stebbins et al., 1999). While the α-domain serves as the EC-binding site, the β-domain plays a role in substrate recognition (Stebbins et al., 1999). Hypoxia-inducible factors, HIF-1α and HIF-2α, have been demonstrated to be targeted for ubiquitylation and degradation under normoxic conditions by physical interaction of its oxygen-dependent degradation domain with the VCB—CUL-2 ligase (Cockman et al., 2000; Kamura et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001). Without functional pVHL, HIF-1α and HIF-2α accumulate in cells, causing the overexpression of HIF target genes such as vascular endothelial growth factor (VEGF), which helps to explain the highly vascular character of VHL tumors and CCRCC. Besides HIF-1α and HIF-2α, other important downstream targets of VCB-CUL2 E3 ubiquitin ligase may exist. There is considerable interest in identifying new downstream targets or interacting proteins of pVHL, which may provide new insights into the biological functions of pVHL. In order to explore further the molecular mechanisms of pVHL-related tumorigenesis, especially in sporadic CCRCC, we used yeast two-hybrid screening to identify previously unknown pVHL-interacting proteins from a kidney cDNA library. Two independent clones identified from this screening encoded the full-length human RNA polymerase II seventh subunit (hsRPB7). RNA and protein expression patterns of hsRPB7 have been studied in different tissues and cell lines (Khazak et al., 1995). A particularly high level of expression for hsRPB7 mRNA and protein levels was observed in normal kidney tissue and the kidney-derived cell line 293 (Khazak et al., 1995). These findings, along with recognition that the specific expression pattern of hsRPB7 mRNA in human tissues differs from that of the largest subunit of RNA polymerase II (hsRPB1) (Khazak et al., 1995), suggest a potential regulatory role for hsRPB7 on gene expression, especially in kidney cells. Here we demonstrate that hsRPB7 is a pVHL-interacting protein and that hsRPB7 can be ubiquitylated and rapidly degraded by a pVHL-mediated ubiquitin—proteasomal pathway in kidney cells. Furthermore, we provide evidence that transcription of VEGF may be regulated by hsRPB7. Our data demonstrate that hsRPB7 is a degradation target of pVHL—E3 ubiquitin ligase, which may represent another important mechanism by which pVHL acts as a renal tumor suppressor. Results hsRPB7 is a novel pVHL-associated protein The human pVHL19 (amino acids 54–213), a biologically functional isoform of pVHL, was used as bait to screen pVHL-interacting partners in a human kidney cDNA library. From a screen of 5.5 × 106 clones, two of the positive clones were identified as encoding the full-length cDNA of hsRPB7. These two clones differed in their 3′ untranslated regions, indicating that they were independent. Subsequent yeast two-hybrid assays showed that yeast cells transformed with either the bait pVHL19 (pGBKT7-VHL19) and pGADT7 vector or the full-length hsRPB7 (pGADT7-hsRPB7) plus pGBKT7 vector did not generate any clones on growth-selection plates (data not shown), while yeast two-hybrid assay using independent retransformation of pGBKT7-VHL19 and pGADT7-hsRPB7, followed by growth selection and a β-galactosidase assay, further confirmed the interaction between pVHL and hsRPB7 in the yeast system (Figure 1A). To demonstrate that these two proteins could physically interact with each other, a GST pulldown assay was performed and the results showed that hsRPB7 could bind directly to GST—VHL19 but not GST alone (Figure 1B). Finally, the results from mammalian two-hybrid assay further confirmed that hsRPB7 interacted with pVHL19 in mammalian cells (Figure 1C). Together, these experiments demonstrated that hsRPB7 could interact with pVHL. Figure 1.pVHL interaction with hsRPB7. (A) Yeast two-hybrid assay followed by a colony lift filter β-Gal assay demonstrates the interaction between pVHL and hsRPB7. Yeast strain AH109 was cotransformed with pGBKT7-VHL19 and pGADT7-hsRPB7 or with pGBKT7-p53 and pGADT7-T (served as a positive control) plated on nutrition dropout selection plates and cultured at 30°C for 3 days, followed by colony-lift filter β-Gal assay. Positive colonies turned blue as shown. (B) hsRPB7 interacts with pVHL in vitro. GST protein and GST—VHL19 fusion protein were expressed in bacteria, purified and incubated with [35S]methionine-labeled hsRPB7. Elutes were separated on a SDS—PAGE gel and detected by phosphoimager. (C) hsRPB7 interacts with pVHL in mammalian cells. pM-VHL19 construct was cotransfected with pVP16-hsRPB7 into COS-7 cells, along with a GAL4-dependent CAT reporter pG5-CAT and a pCMV-β-Gal expression vector. The β-Gal vector served as an internal control for normalization of transfection efficiency. Control experiments with pM-BD or pVP16-AD alone were also conducted in parallel. (D) Mapping the hsRPB7-interacting region in pVHL. In (a), 10% of in vitro translated 35S-labeled hsRPB7 was used as a positive control, and in vitro translated 35S-labeled hsRPB7 protein was incubated with beads coated with GST, GST—VHL19, GST—VHL54–113, GST—VHL114–213, GST—VHL-P86H and GST—VHL-Y98H, respectively. The bound proteins were eluted and analyzed on SDS—PAGE gel. Equal amounts of viable GST—VHL fusion proteins were demonstrated. Relative binding abilities of hsRPB7 and pVHL fragments were analyzed in (b). Results are expressed as the mean ± SD of three independent experiments. (E) Extracts of HeLa cells and 786-O cells treated with or without MG132 were used in immunoprecipitation (IP) assay by pVHL antibody. Precipitates were resolved on SDS—PAGE gels and immunoblotted (IB) with hsRPB7, VHL and EC antibodies, respectively. Download figure Download PowerPoint To determine the hsRPB7-interacting region in pVHL, GST pulldown assays were performed with pVHL fragments covering different regions. GST—VHL19 and GST—VHL54–113, but not GST—VHL114–213, could retain the in vitro translated hsRPB7 protein (Figure 1D). These results suggest that hsRPB7 interacts with pVHL within residues 54–113. This region is a part of the β-domain of pVHL, which is responsible for substrate recognition for ubiquitylation and degradation. Many missense mutations found in VHL disease or renal cell carcinomas occur in this region. We further tested the interactions between hsRPB7 and several common VHL mutants that harbor naturally occurring point mutations in the β-domain. Also demonstrated in Figure 1D, two representative pVHL mutants harboring mutations in the β-domain (P86H and Y98H, respectively) showed a reduced binding capacity between pVHL and hsRPB7 (Figure 1D, a and b). In vivo co-immunoprecipitation was performed using the HeLa cell line, which contains endogenous wild-type pVHL, and the 786-O cell line, which contains mutant pVHL (truncated pVHL with the intact β-domain but missing the α-domain). pVHL antibody can recognize and precipitate this mutant form of pVHL. To demonstrate that pVHL and hsRPB7 could interact with each other in their natural forms, cultured HeLa cells were treated with or without MG132 (a proteasomal inhibitor) and lysates of these cells were immunoprecipitated with pVHL antibody, and then fractionated on SDS—PAGE gels and immunoblotted with anti-hsRPB7, pVHL and EC antibodies, respectively. As shown in Figure 1E, hsRPB7 can be found in the immunoprecipitates against endogenous pVHL in HeLa cells. In HeLa cells without proteasomal inhibitor MG132 treatment, the amount of hsRPB7 associated with pVHL was significantly less compared with MG132-treated HeLa cells, indicating that rapid turnover of hsRPB7 occurred after a brief interaction with pVHL under normal conditions. As expected, EC was associated with pVHL either with or without MG132 treatment. In contrast, in 786-O cells, endogenous mutant pVHL can be found associated with hsRPB7; MG132 treatment did not make any difference in the interaction. As expected, mutant pVHL without the α-domain failed to precipitate EC. Co-immunoprecipitation was also performed with an anti-RNA polymerase II (anti-Pol II) C-terminal domain (CTD) antibody. hsRPB7 was detected in the precipitates, but not pVHL (data not shown). This indicates that hsRPB7 does not recruit pVHL into the Pol II complex. Taken together, the above in vitro and in vivo data demonstrate that hsRPB7 is a pVHL β-domain-associated protein, and, more importantly, the above results indicate that hsRPB7 may degrade through the proteasome degradation pathway. The following experiments further explore the functional significance of this interaction. Ubiquitylation of hsRPB7 is pVHL dependent To test whether hsRPB7 can be ubiquitylated by pVHL—E3 ubiquitin ligase, we performed a series of in vitro and in vivo ubiquitylation assays. HeLa cell cytoplasmic extracts (S-100) were incubated with [35S]methionine-labeled hsRPB7. Incubation of the extracts along with an ATP regeneration system converted the hsRPB7 substrate to multiple slower migrating forms (Figure 2A), indicating that the hsRPB7 could be polyubiquitylated. To determine the role of pVHL19 in hsRPB7 ubiquitylation, we performed similar assays using extracts from 786-O cells. This kidney cancer cell line contains non-functional pVHL. Our results showed that the 786-O cell extracts with transfected wild-type pVHL19 (pcDNA4-VHL19) resulted in the ubiquitylation of hsRPB7, whereas with pcDNA4 vector only, the 786-O cell extracts were unable to lead to polyubiquitylation of hsRPB7. The authenticity of ubiquitylation was confirmed by incorporating UbK48R and methylated ubiquitin into the assays (Figure 2A and B). This pVHL-dependent ubiquitylation was also specific to hsRPB7, because the ubiquitylation of p53, which was tested under the same conditions, was not affected by the addition of pVHL19 (data not shown). Furthermore, this pVHL-dependent ubiquitylation process was diminished when using naturally occurring VHL missense mutations in its β-domain that disrupt the interaction between hsRPB7 and pVHL (Figure 2C). In vitro ubiquitylation of hsRPB7 using recombinant E1 and E2 (UbcH5a) was also tested (Figure 2D). VBC complex was immunoprecipitated from HeLa cells (Iwai et al., 1999). hsRPB7 could only be ubiquitylated in the presence of E1, E2 and VBC complex, and the intensity of ubiquitylation is directly dependent on the amount of VBC complex (Figure 2E). Finally, in vivo ubiquitylation was performed using kidney 786-O cells. Transfection of wild-type pVHL19 led hsRPB7 to become a ubiquitylated form, which further confirmed the previous in vitro results (Figure 2F) and demonstrated that ubiquitylation of hsRPB7 is pVHL dependent. Figure 2.pVHL-dependent ubiquitylation of hsRPB7. (A) In vitro ubiquitylation of hsRPB7 by HeLa cell cytoplasmic extracts (S-100). 35S-labeled hsRPB7 was used as a substrate in reactions of different compositions for 2 h. The positions of the non-ubiquitylated and ubiquitylated hsRPB7 are indicated. The amounts of endogenous pVHL19 are depicted by western blot. (B) pVHL-dependent hsRPB7 ubiquitylation. 35S-labeled hsRPB7 was incubated at 37°C for 2 h in reactions consisting of 786-O cell extracts transfected with pcDNA4 vector or pcDNA4-VHL19, ATP-regenerating system, ubiquitin or methylated ubiquitin and ubiquitin-aldehyde (UbAl). Ubiquitylation of hsRPB7 was only found in the presence of pVHL19. The expression of His—pVHL19 was detected by anti-His immunoblot. (C) The effect of several pVHL mutations on the hsRPB7 ubiquitylation. 786-O cells were tranfected with wild-type pVHL or pVHL mutant constructs. No ubiquitylation was detected in the presence of pVHL mutants (pcDNA4-VHLP86H and pcDNA4-VHLY98H). The expressions of variable His—pVHL19 mutants were detected by anti-His immunoblot. (D) pVHL-dependent ubiquitylation of hsRPB7 in vitro by recombinant E1 and E2. 35S-labeled hsRPB7 was incubated at 37°C for 2 h in reactions consisting of E1, E2 or VBC complex or control IgG immunoprecipitates. Ubiquitylation of hsRPB7 was only found in the presence of E1, E2 and VBC complex. Endogenous VBC complex (VHL, EB, EC) was detected by western blot. (E) Ubiquitylation of hsRPB7 in vitro is in a VBC complex-dependent fashion. The amount of hsRPB7 ubiquitylation is VBC complex dose dependent. (F) pVHL-dependent ubiquitylation of hsRPB7 in vivo. 786-O cells were cotransfected with pCMV-flag-hsRPB7 and pcDNA4-VHL19 or pCMV-flag-hsRPB7 and pcDNA4 vector. Cell extracts were immunoprecipitated by flag antibody, resolved on SDS—PAGE gel and detected by anti-flag and anti-ubiquitin antibodies independently. Download figure Download PowerPoint pVHL mediates the proteasomic degradation of hsRPB7 To test whether this ubiquitylation mediated by pVHL will result in a rapid turnover of hsRPB7, we examined the degradation of hsRPB7 in kidney tumor cell lines A498 and 786-O. A498 cells were transiently transfected with an empty vector (pcDNA4), wild-type pVHL19 (pcDNA4-pVHL19) and pVHL114–213 (without the hsRPB7 interaction region), respectively. MG132 treatment was also used in a separate panel in combination with wild-type pVHL19 (pcDNA4-VHL19). Equal amounts of total protein were loaded into each lane. As shown in Figure 3A, overexpression of pVHL19 decreased the amount of endogenous hsRPB7 in A498 cells and, importantly, this effect was reversible by a combined treatment with MG132. MG132 alone did not significantly increase the level of hsRPB7 protein (data not shown). pVHL114–213 without the hsRPB7-binding domain did not exhibit the ability to decrease hsRPB7 levels. As a control, a northern blot was performed and no change in hsRPB7 mRNA levels was observed following transfection with wild-type pVHL19, making it very unlikely that pVHL19 influences hsRPB7 at the mRNA level (data not shown). To evaluate further the effect of pVHL on the degradation of hsRPB7, pulse—chase assays were performed in 786-O cells. As shown in Figure 3B (a), after cycloheximide treatment, hsRPB7 was quite stable in the group transfected with pcDNA4 vector only. In contrast, the hsRPB7 level decreased dramatically when transfected with wild-type pVHL. The cycloheximide treatment led to a significant decrease in hsRPB7 protein level and MG132 treatment restored the hsRPB7 protein level (Figure 3B, b). Taken together, these data demonstrated that the hsRPB7 protein was undergoing proteasome-dependent degradation in a pVHL-dependent manner, indicating that hsRPB7 is a downstream target of pVHL—E3 ligase for ubiquitylation and rapid degradation by proteasome. Figure 3.pVHL mediates proteasomal degradation of hsRPB7. (A) pVHL-dependent proteasomal degradation of hsRPB7 in A498 cells. In (a), A498 cells were transfected with empty pcDNA4 vectors, pcDNA4-VHL19 or pcDNA4-VHL114–213 with or without MG132 treatment as indicated. Fifty micrograms of whole-cell lysates were loaded in each lane. The expressions of pVHL fragments were detected by anti-His western blot. Immunoblots (IB) were performed against hsRPB7 and p62 (the p62 subunit of TFIIH was used as a loading control). Relative hsRPB7 amounts were quantitated and are shown in (b). Results are expressed as the mean ± SD of three independent experiments. (B) pVHL-dependent proteasomal degradation of hsRPB7 in 786-O cells. In (a), 786-O cells were transfected with pcDNA4 vector or pcDNA4-VHL19. Cells were treated with 5 μM MG132 or DMSO. Six hours later, cells were incubated with cycloheximide (CHX) for 0, 2, 4 and 6 h, as indicated above. Fifty micrograms of whole-cell lysates were loaded in each lane. Immunoblotting (IB) was performed by using hsRPB7 antibody. P62 was detected to demonstrate equal loading of each sample and relative hsRPB7 amounts are quantitated in (b). Download figure Download PowerPoint pVHL decreases nuclear accumulation of endogenous hsRPB7 To test whether pVHL has any influence on the subcellular localization of hsRPB7, dual immunofluorescence staining with pVHL antibody (for endogenous pVHL protein when transfected with empty vector only) or anti-His6 antibody (for His6 wild-type or mutant pVHL fusion proteins) and hsRPB7 antibody was performed using 786-O tumor cells, which express an endogenous mutant non-functional pVHL. FITC green fluorescence staining of endogenous hsRPB7 is shown in Figure 4, column 1 (A1–E1) and rhodamine red staining of endogenous pVHL (A2) or transfected His6-tagged wild-type or mutant pVHL (B2–F2) is shown in Figure 4, column 2. Merged images of column 1 and column 2 are shown in column 3. DAPI staining in column 4 demonstrates the nuclear positions of corresponding cells. Cells in Figure 4 (rows A–E) were transfected with pcDNA4 vector (row A), pcDNA4-VHL19 (row B), pcDNA4-VHL114-213 (row C), pcDNA4-VHL-P86H (row D) and pcDNA4-VHL-Y98H (row E), respectively. As shown in Figure 4 (A1–A4), with transfection of empty pcDNA4 vectors alone, endogenous hsRPB7 was localized in both the nucleus and cytoplasm with strong staining in the nucleus (A1 and A3). In contrast, after introducing wild-type pVHL19 (pcDNA4-VHL19), which was mainly localized in the cytoplasm (B2), into the cells, hsRPB7 nuclear accumulation was decreased dramatically (B1 and B3). This effect cannot be found by using mutant pVHL, including cells transfected with pcDNA4-VHL114–213 (C1 and C3), pcDNA4-VHL-P86H (D1 and D3) or pcDNA4-VHL-Y98H (E1 and E3), which either lost or had a reduced binding capacity to hsRPB7, as demonstrated in our earlier results (Figure 1D). To test whether the effect of pVHL on the distribution of hsRPB7 is specific, another RNA Pol II subunit, hsRPB4, was tested. As shown in Figure 4 (F1–F4), transfection of wild-type pVHL did not decrease the nuclear accumulation of this protein, confirming the specificity of this process. These phenomena suggest that wild-type pVHL19 facilitates degradation of hsRPB7 and intact interaction region of the β-domain is required for this process. Figure 4.Decreased nuclear accumulation of endogenous hsRPB7 by pVHL. 786-O cells were transfected with pcDNA4 vector, pcDNA4-VHL19, pcDNA4-VHL114–213, pcDNA4-VHL-P86H and pcDNA4-VHL-Y98H, respectively, as indicated. Endogenous hsRPB7, hsRPB4 and pVHL or His6-tagged wild-type or mutant pVHL fusion proteins were detected by double-immunostaining with hsRPB7 or hsRPB4 rabbit polyclonal antibody and pVHL mouse monoclonal antibody or anti-His6 mouse monoclonal antibody (for His6—pVHL fusion proteins), followed by FITC green conjugated secondary antibody for visualizing hsRPB7 (column 1, A1—E1) and hsRPB4 (column 1, F1), and rhodamine red-conjugated secondary antibody for endogenous pVHL (column 2, A2) or His6-tagged pVHL (column 2, B2—F2). Merged images of columns 1 and 2 are shown in column 3. DAPI staining in column 4 demonstrates the nucleus positions of corresponding cells. Note that the nuclear intensity of hsRPB7, but not hsRPB4, dramatically decreases only in the presence of wild-type pVHL19 (indicated by arrow). Download figure Download PowerPoint hsRPB7 enhances VEGF transactivation, VEGF mRNA expression and VEGF protein secretion in kidney cancer cells To explore the biological consequence of pVHL-mediated hsRPB7 degradation, we examined whether hsRPB7 could influence VEGF expression by testing the effects of hsRPB7 on VEGF promoter transactivation, endogenous VEGF mRNA expression and protein secretion. A498 and 786-O cell lines were used in our study. Transfection of hsRPB7 plasmid at a 3:1 ratio relative to the VEGF promoter plasmid caused a 1.5- to 2-fold increase in the VEGF promoter activity in A498 and 786-O cells (Figure 5A). Introducing a pVHL expression plasmid at a 3:1 ratio to the VEGF promoter plasmid decreased VEGF transactivation by 30–50%. Cotransfection of pVHL with hsRPB7 expression plasmids at a 3:3:1 ratio to the VEGF promoter plasmid abolished the hsRPB7-mediated transactivation of the VEGF promoter in A498 and 786-O cells (Figure 5A). Our results demonstrated that hsRPB7 could enhance VEGF transactivation and this effect could be reversed by wild-type pVHL. The specificity of the transactivation effect of hsRPB7 on the VEGF promoter was further tested by using the androgen response element promoter and the fibrinogen promoter. No transactivation effects were observed (data not shown). Figure 5.The effects of hsRPB7 on transactivation of the VEGF promoter, VEGF mRNA expression and VEGF secretion. (A) hsRPB7 enhances VEGF transactivation. A498 and 786-O cell lines were cotransfected with combinations of pGL3-VEGF promoter construct, pRL-SV40, pcDNA4-hsRPB7 and pcDNA4-VHL19 as indicated. The firefly luciferase activity from the VEGF promoter was normalized by Renilla luciferase activity. The relative luciferase activity of cells transfected with vector only was set as basal level. Results are expressed as the mean ± SD of three independent experiments. (B) hsRPB7 promotes VEGF secretion. A498 and 786-O cell lines were transfected with pcDNA4-hsRPB7 and/or pcDNA4-VHL19 as indicated. VEGF secretion into the medium was quantitated using ELISA assays and normalized by an equal amount of total proteins from each sample. Results are expressed as the mean ± SD of three independent experiments. (C) hsRPB7 enhances VEGF